United-Guardian (UG) Q3 2026 earnings summary

Executive summary

• Q3 2026 net sales rose 54% YoY to $3.49M; net income increased 247% to $930,912 from $268,441.

• 9M net sales rose 25% to $9.48M and net income increased to $2,478,393 from $1,456,162; growth spanned pharmaceuticals, cosmetic ingredients and medical lubricants.

Financial highlights

• Q3 operating income was $1,108,928 versus $215,072; 9M operating income was $2,505,502 versus $1,521,447.

• Q3 net income was $930,912, or $0.20 per diluted share, versus $268,441, or $0.06; 9M net income was $2,478,393, or $0.54 per share, versus $1,456,162, or $0.32.

• Operating expenses rose 4% in Q3 and 2% in 9M; R&D expense rose 4% and 6%, respectively.

Outlook and guidance

• Expected FY 2026 effective tax rate is 21%; working capital is expected to support operating requirements for at least 12 months.

• A personal care product is in late-stage development, with launch planned for early 2027.

• Renacidin payer outreach and healthcare-professional awareness efforts are planned; two major PBMs added Renacidin to formularies effective June 1 and July 1, 2026.